TY - JOUR
T1 - Expression characteristics of prostate-derived Ets factor support a role in breast and prostate cancer progression
AU - Sood, Ashwani K.
AU - Saxena, Rakhee
AU - Groth, Jeff
AU - Desouki, Mohamed M.
AU - Cheewakriangkrai, Chalong
AU - Rodabaugh, Kerry J.
AU - Kasyapa, Chitta S.
AU - Geradts, Joseph
N1 - Funding Information:
This work was supported by grant CA 86164 from the National Cancer Institute and by grant BC045095 from the US Army. The institutional core facilities used in this research were supported by Roswell Park Cancer Center Support grant P30CA16056 (Buffalo, NY). The authors do not have a financial conflict of interest in regard to this study.
PY - 2007/11
Y1 - 2007/11
N2 - The purpose of this study was to understand the characteristics of prostate-derived Ets factor (PDEF) protein expression in breast and prostate cancer progression. A polyclonal antibody specific to PDEF was raised and reacted with tissue microarrays consisting of benign breast, in situ ductal, invasive ductal, and invasive lobular breast carcinomas. The antibody was also reacted with tissue microarrays, including benign prostate, prostate intraepithelial neoplasias (PINs), and prostate carcinomas. Increased expression of PDEF was identified in 18%, 50%, 46%, and 51% of benign breast tissues, intraductal, invasive ductal, and invasive lobular carcinomas, respectively. Importantly, in matched samples of benign breast vs tumor, 90% showed higher expression of PDEF in the tumor tissue. Moreover, in invasive breast carcinomas, increased PDEF expression tended to correlate with Her2/neu overexpression. Increased expression of PDEF was also found in 27%, 33%, and 40% of benign prostate tissues, PIN samples, and prostate adenocarcinomas, respectively. Again, in matching samples of cancer vs benign and cancer vs PIN, 68% and 70%, respectively, showed increased expression in the malignant tissue. Moreover, PDEF was found to be more highly expressed in tumors with intermediate or high Gleason score compared with low-grade tumors (P < .01). In addition, R1881 treatment induced PDEF expression in the LNCaP prostate tumor cell line, suggesting regulation of PDEF by androgens in vivo. Together, these results for the first time show frequent increased expression of PDEF protein in breast and prostate tumors and support a role for PDEF in breast and prostate cancer progression.
AB - The purpose of this study was to understand the characteristics of prostate-derived Ets factor (PDEF) protein expression in breast and prostate cancer progression. A polyclonal antibody specific to PDEF was raised and reacted with tissue microarrays consisting of benign breast, in situ ductal, invasive ductal, and invasive lobular breast carcinomas. The antibody was also reacted with tissue microarrays, including benign prostate, prostate intraepithelial neoplasias (PINs), and prostate carcinomas. Increased expression of PDEF was identified in 18%, 50%, 46%, and 51% of benign breast tissues, intraductal, invasive ductal, and invasive lobular carcinomas, respectively. Importantly, in matched samples of benign breast vs tumor, 90% showed higher expression of PDEF in the tumor tissue. Moreover, in invasive breast carcinomas, increased PDEF expression tended to correlate with Her2/neu overexpression. Increased expression of PDEF was also found in 27%, 33%, and 40% of benign prostate tissues, PIN samples, and prostate adenocarcinomas, respectively. Again, in matching samples of cancer vs benign and cancer vs PIN, 68% and 70%, respectively, showed increased expression in the malignant tissue. Moreover, PDEF was found to be more highly expressed in tumors with intermediate or high Gleason score compared with low-grade tumors (P < .01). In addition, R1881 treatment induced PDEF expression in the LNCaP prostate tumor cell line, suggesting regulation of PDEF by androgens in vivo. Together, these results for the first time show frequent increased expression of PDEF protein in breast and prostate tumors and support a role for PDEF in breast and prostate cancer progression.
KW - Breast cancer
KW - Gleason score
KW - PDEF
KW - Prostate cancer
KW - R1881
KW - Tumor marker and target
UR - http://www.scopus.com/inward/record.url?scp=35348902518&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=35348902518&partnerID=8YFLogxK
U2 - 10.1016/j.humpath.2007.03.010
DO - 10.1016/j.humpath.2007.03.010
M3 - Article
C2 - 17521701
AN - SCOPUS:35348902518
SN - 0046-8177
VL - 38
SP - 1628
EP - 1638
JO - Human Pathology
JF - Human Pathology
IS - 11
ER -